Treatment of severe hypertension in end-stage renal failure: Effect of renal denervation in dialysis patients and patients with renal transplant.

Treatment of severe hypertension in end-stage renal failure: Effect of renal denervation in dialysis patients and patients with renal transplant. - Renal denervation in ESRF

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39799

Enrollment

Registered

2013-05-01

Start date

2013-01-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high blood pressure hypertension

Interventions

Renal denervation with an ablationcatheter. The renal arteries of the native kidneys will be denervated.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with a renal transplant or on dialysis with therapy resistent hypertension, as defined in current guidelines (SBP >160 mmHg with the use of >=3 antihypertensive medication).

Exclusion criteria

Exclusion criteria: Patient with a renal artery stent. Pregnant or pregnancy desire. Known allergy for iodine contrast. Age

Design outcomes

Primary

Measure	Time frame
Primary study outcome is the degree of blood pressure drop in 6 months after renal denervation. Measurements will be performed with ambulatory blood pressure measurement during 24 hours. Also changes in medication regimen will be registered.	—

Secondary

Measure	Time frame
Effect of renal denervation on cardiac mass and function. Changes in sympatic nerve activity measured by EMG of the nervus peroneus. Changes in hormonal levels related to blood pressure regulation.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)